This is a regulatory disclosure submitted to BSE Limited in compliance with SEBI Listing Regulations. The primary purpose of the document is to intimate the exchange about the dispatch of communications to shareholders regarding the availability of the Annual Report and the notice for the upcoming Annual General Meeting (AGM).
The 32nd Annual General Meeting of Novelix Pharmaceuticals Limited is scheduled to be held on Wednesday, September 30, 2026, at 3:00 P.M. (IST). The meeting will be conducted through Video Conferencing / Other Audio Visual Means.
This communication is specifically being sent to shareholders whose e-mail IDs are not registered with the Company, its Registrar and Transfer Agent (RTA), Venture Capital and Corporate Investments Private Limited, or their Depository Participants. This action is undertaken to comply with Regulation 36(1)(b) of the SEBI Listing Regulations.
The complete Annual Report for the Financial Year 2025-26 and the Notice of the 32nd AGM are available for download from the Company's website at the following dedicated link: https://novelixpharma.com/annual-report/.
The document serves as a reminder and provides instructions for shareholders to update their communication preferences and KYC details:
- For physical shareholders: Must submit the SEBI-prescribed ISR form to the Company's RTA, M/s Venture Capital and Corporate Investments Pvt. Ltd., to register their email ID. The form is available on the company's website (
www.novelixpharma.com) or the RTA's website (https://www.vccipl.com/index.html#services). - For demat shareholders: Should contact their respective Depository Participant (DP) to update their email address.
A further reminder is issued for shareholders to update their KYC details (PAN, Address, Mobile Number, Bank Account, Specimen Signature, and Nomination) as mandated by SEBI Master Circular No. SEBI/HO/MIRSD/POD-1/P/CIR/2024/37 dated May 07, 2024. Shareholders holding physical shares are also encouraged to dematerialize their securities.
The relevant forms (ISR-1, ISR-2, ISR-3, SH-13, SH-14) are available on the RTA's website.
For queries, shareholders can contact:
- Company's Investor Relations:
novelixpharmaceuticals@gmail.com - Company's RTA, Venture Capital and Corporate Investments Pvt. Limited:
info@vccipl.comor Phone: 040-23818475/476
Financial Impact: This disclosure pertains to corporate governance and communication procedures. No direct financial impact is quantified in the disclosure.